ZA868943B - Eukaryotic fusion proteins,the preparation and use thereof,and means for carrying out the process - Google Patents

Eukaryotic fusion proteins,the preparation and use thereof,and means for carrying out the process

Info

Publication number
ZA868943B
ZA868943B ZA868943A ZA868943A ZA868943B ZA 868943 B ZA868943 B ZA 868943B ZA 868943 A ZA868943 A ZA 868943A ZA 868943 A ZA868943 A ZA 868943A ZA 868943 B ZA868943 B ZA 868943B
Authority
ZA
South Africa
Prior art keywords
fusion proteins
new
preparation
carrying
derivs
Prior art date
Application number
ZA868943A
Inventor
Paul Habermann
Friedrich Wengenmayer
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of ZA868943B publication Critical patent/ZA868943B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/815Protease inhibitors from leeches, e.g. hirudin, eglin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/35Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Fusion proteins in which the C- or N-terminal essentially corresponds to the first 100 units of interleukin 2 are new. Also new are gene structures coding for the above fusion proteins, vectors containing these gene structures, and hot cells containing these vectors. Hirudin derivs. with an amino acide sequence begining N-terminally with Pro are new and claimed. Human interleukin 2 derivs. contg. Asp. C-terminally are new and claimed.
ZA868943A 1985-11-27 1986-11-26 Eukaryotic fusion proteins,the preparation and use thereof,and means for carrying out the process ZA868943B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19853541856 DE3541856A1 (en) 1985-11-27 1985-11-27 EUKARYOTIC FUSION PROTEINS, THEIR PRODUCTION AND USE, AND MEANS FOR CARRYING OUT THE PROCESS

Publications (1)

Publication Number Publication Date
ZA868943B true ZA868943B (en) 1987-07-29

Family

ID=6286938

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA868943A ZA868943B (en) 1985-11-27 1986-11-26 Eukaryotic fusion proteins,the preparation and use thereof,and means for carrying out the process

Country Status (17)

Country Link
EP (3) EP0227938B1 (en)
JP (1) JP2566933B2 (en)
KR (1) KR950000300B1 (en)
AT (2) ATE127841T1 (en)
AU (1) AU595262B2 (en)
CA (1) CA1341203C (en)
DE (4) DE3541856A1 (en)
DK (2) DK172064B1 (en)
ES (3) ES2073081T3 (en)
FI (1) FI93471C (en)
GR (1) GR3005042T3 (en)
HU (1) HU203579B (en)
IE (1) IE59488B1 (en)
IL (1) IL80755A0 (en)
NO (1) NO176481C (en)
PT (1) PT83813B (en)
ZA (1) ZA868943B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3125021A (en) * 1955-11-14 1964-03-17 Smooth
EP0168342B1 (en) * 1984-06-14 1991-07-03 Ciba-Geigy Ag Process for the preparation of thrombin inhibitors
DE3545568A1 (en) * 1985-12-21 1987-07-16 Hoechst Ag GM-CSF-PROTEIN, ITS DERIVATIVES, PRODUCTION OF SUCH PROTEINS AND THEIR USE
DE3712985A1 (en) * 1987-04-16 1988-11-03 Hoechst Ag BIFUNCTIONAL PROTEINS
DE3819079A1 (en) * 1988-06-04 1989-12-07 Hoechst Ag HIRUDINE DERIVATIVES WITH DELAYED EFFECT
DE3835815A1 (en) * 1988-10-21 1990-04-26 Hoechst Ag NEW ISOHIRUDINE
DE3844211A1 (en) * 1988-12-29 1990-07-05 Hoechst Ag NEW INSULINE DERIVATIVES, THE PROCESS FOR THEIR PRODUCTION, THEIR USE AND A PHARMACEUTICAL PREPARATION CONTAINING THEM
US5179196A (en) * 1989-05-04 1993-01-12 Sri International Purification of proteins employing ctap-iii fusions
WO1991000912A1 (en) * 1989-07-07 1991-01-24 Massachusetts Institute Of Technology Production and use of hybrid protease inhibitors
CU22222A1 (en) * 1989-08-03 1995-01-31 Cigb PROCEDURE FOR THE EXPRESSION OF HETEROLOGICAL PROTEINS PRODUCED IN A FUSION FORM IN ESCHERICHIA COLI, ITS USE, EXPRESSION VECTORS AND RECOMBINANT STRAINS
GB8927722D0 (en) * 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
DE3942580A1 (en) * 1989-12-22 1991-06-27 Basf Ag METHOD FOR PRODUCING HIRUDINE
US5270181A (en) * 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
DE4140381A1 (en) * 1991-12-07 1993-06-09 Hoechst Ag, 6230 Frankfurt, De NEW SYNTHETIC ISOHIRUDINE WITH IMPROVED STABILITY
DE4404168A1 (en) * 1994-02-10 1995-08-17 Hoechst Ag Hirudin derivatives and process for their preparation
DK0821006T3 (en) 1996-07-26 2004-08-16 Aventis Pharma Gmbh Insulin derivatives with increased zinc binding
DE19726167B4 (en) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, process for its preparation and pharmaceutical preparation containing it
DE19825447A1 (en) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh New insulin analogues with increased zinc formation
DE10033195A1 (en) * 2000-07-07 2002-03-21 Aventis Pharma Gmbh Bifunctional fusion proteins from hirudin and TAP
US7638618B2 (en) 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
DE10114178A1 (en) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinc-free and low-zinc insulin preparations with improved stability
DE10227232A1 (en) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Sour insulin preparations with improved stability
HUE037449T2 (en) 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Combination of an insulin and a glp-1 agonist
AR080669A1 (en) 2009-11-13 2012-05-02 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION INCLUDING A GLP-1 AGONIST, AN INSULIN AND METIONIN
WO2011058082A1 (en) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist and methionine
ES2606554T3 (en) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the manufacture of a medication for the treatment of type 2 diabetes mellitus
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
BR112014004726A2 (en) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland pharmaceutical combination for use in glycemic control in type 2 diabetes patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
PL3229828T3 (en) 2014-12-12 2023-07-31 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
KR20200080748A (en) 2018-12-27 2020-07-07 주식회사 폴루스 A Method for Purifying Proinsulin Using Anion Exchange Chromatography
KR20200080747A (en) 2018-12-27 2020-07-07 주식회사 폴루스 An Enzymatic Conversion Composition for Producing Insulin from Proinsulin and a Method for Producing Insulin from Proinsulin Using the Same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
DK108685A (en) * 1984-03-19 1985-09-20 Fujisawa Pharmaceutical Co GROWTH FACTOR I
CA1341414C (en) * 1984-03-27 2002-12-31 Paul Tolstoshev Expression vectors of hirudine, transformed cells and process for the preparation of hirudine
EP0158198A1 (en) * 1984-03-29 1985-10-16 Takeda Chemical Industries, Ltd. DNA and use thereof
DE3429430A1 (en) * 1984-08-10 1986-02-20 Hoechst Ag, 6230 Frankfurt GENE TECHNOLOGICAL METHOD FOR PRODUCING HIRUDINE AND MEANS FOR IMPLEMENTING THIS METHOD
DE3526995A1 (en) * 1985-07-27 1987-02-05 Hoechst Ag FUSION PROTEINS, METHOD FOR THEIR PRODUCTION AND THEIR USE
CA1297003C (en) * 1985-09-20 1992-03-10 Jack H. Nunberg Composition and method for treating animals
US4865974A (en) * 1985-09-20 1989-09-12 Cetus Corporation Bacterial methionine N-terminal peptidase

Also Published As

Publication number Publication date
DK172064B1 (en) 1997-10-06
EP0227938A2 (en) 1987-07-08
HU203579B (en) 1991-08-28
DK172210B1 (en) 1998-01-05
FI864798A (en) 1987-05-28
ES2032378T3 (en) 1993-02-16
IE59488B1 (en) 1994-03-09
IE863119L (en) 1987-05-27
AU6569386A (en) 1987-06-04
ES2073081T3 (en) 1995-08-01
DE3684892D1 (en) 1992-05-21
PT83813A (en) 1986-12-01
IL80755A0 (en) 1987-02-27
HUT43642A (en) 1987-11-30
DK568586D0 (en) 1986-11-26
KR870005098A (en) 1987-06-04
DE3650396D1 (en) 1995-10-19
PT83813B (en) 1989-06-30
KR950000300B1 (en) 1995-01-13
GR3005042T3 (en) 1993-05-24
DK52292A (en) 1992-04-21
ATE122397T1 (en) 1995-05-15
EP0227938A3 (en) 1988-11-23
ATE127841T1 (en) 1995-09-15
NO864759D0 (en) 1986-11-26
JP2566933B2 (en) 1996-12-25
DE3650322D1 (en) 1995-06-14
ES2077747T3 (en) 1995-12-01
EP0468539A1 (en) 1992-01-29
DE3541856A1 (en) 1987-06-04
NO176481B (en) 1995-01-02
NO176481C (en) 1995-04-12
EP0227938B1 (en) 1992-04-15
FI93471C (en) 1995-04-10
FI864798A0 (en) 1986-11-25
CA1341203C (en) 2001-03-13
FI93471B (en) 1994-12-30
DK52292D0 (en) 1992-04-21
EP0468539B1 (en) 1995-09-13
AU595262B2 (en) 1990-03-29
DK568586A (en) 1987-05-28
JPS62143696A (en) 1987-06-26
EP0464867B1 (en) 1995-05-10
EP0464867A1 (en) 1992-01-08

Similar Documents

Publication Publication Date Title
ZA868943B (en) Eukaryotic fusion proteins,the preparation and use thereof,and means for carrying out the process
NZ218332A (en) Il-4(interleukin-4), recombinant production, dna, vectors and pharmaceutical composition
FR2681786B1 (en)
MY102546A (en) Human immune interferon
UA27706C2 (en) Method of obtaining heterologous polypeptide
GB2181138B (en) Recombinant alveolar surfactant protein
ES8307297A1 (en) Polypeptides, process for their microbial production, intermediates therefor and compositions containing them.
ES8704207A1 (en) Rhinovirus strain HRV2 polypeptides and DNA molecules encoding them.
DE3881023D1 (en) PROTEINS, EXPRESSION VECTORS, CONTAINING DNA ENCODING SUCH PROTEINS, AND CELLS CONTAINING SUCH EXPRESSION VECTORS.
GB2171703B (en) Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re
EP0165759A3 (en) Mammalian promotors useful in yeast expression